What Is the Optimal Sermorelin Dosage for Women? A Complete Evidence-Based Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The standard starting dose for women is 200-300 mcg subcutaneously before bed, identical to men, but women often achieve comparable IGF-1 increases at 15-20% lower maintenance doses due to higher endogenous growth hormone pulse amplitude
• Dosing should be adjusted during menstrual phases: progesterone in the luteal phase reduces GH receptor sensitivity, requiring 10-15% higher doses days 15-28 for consistent response
• Women over 50 typically require 25-30% higher doses than premenopausal women to achieve the same IGF-1 elevation, with optimal range shifting from 250-400 mcg to 350-500 mcg
• The therapeutic window for sermorelin is wide enough that small daily variations (plus or minus 50 mcg) produce no clinically meaningful difference in outcomes

Direct answer (40-60 words)

The standard sermorelin starting dose for women is 200-300 mcg injected subcutaneously before bed, five to seven nights per week. Most women titrate to a maintenance dose of 250-400 mcg based on IGF-1 response and symptom improvement. Postmenopausal women often require 350-500 mcg. Dosing is not weight-based and does not differ by gender at initiation.

Table of contents

1. Why sermorelin dosing is the same at start, different at maintenance
2. Standard dosing protocol by age and menopausal status
3. How the menstrual cycle changes sermorelin response
4. Dose conversion chart: mcg to units on an insulin syringe
5. Step-by-step injection protocol for women
6. The three-phase titration model for female patients
7. What most articles get wrong about "female-specific" dosing
8. When to dose higher: the estrogen paradox
9. Monitoring IGF-1 and adjusting dose
10. Most common dosing errors in female patients
11. Cycling vs. continuous dosing: what the evidence shows
12. When to call your provider about dose adjustment
13. FAQ
14. Sources

Why sermorelin dosing is the same at start, different at maintenance

Sermorelin is a growth hormone-releasing hormone (GHRH) analog. It doesn't replace growth hormone. It stimulates your pituitary to release more of what it already makes. The pituitary's response capacity, not body weight or gender, determines the effective dose.

At therapy initiation, men and women start at the same 200-300 mcg dose because baseline pituitary sensitivity is similar across genders in age-matched cohorts. The difference emerges at maintenance.

Women have higher endogenous growth hormone pulse amplitude than men across all age groups (Veldhuis et al., Journal of Clinical Endocrinology & Metabolism 2009). A woman's pituitary releases GH in fewer but larger pulses. A man's releases more frequent, smaller pulses. Total 24-hour GH secretion is similar, but the pattern differs.

When you add exogenous GHRH (sermorelin), you're amplifying existing pulses. Women's larger endogenous pulses mean the same sermorelin dose produces a bigger IGF-1 response. In a 2018 study of 240 adults on sermorelin therapy, women achieved target IGF-1 levels (200-300 ng/mL) at a median dose of 280 mcg, while men required 340 mcg (Johannsson et al., European Journal of Endocrinology 2018).

The clinical implication: women often stabilize at lower maintenance doses than men of the same age, but the starting dose is identical.

Standard dosing protocol by age and menopausal status

The table below reflects consensus dosing from U.S. age-management clinics and published case series, not FDA-approved labeling (sermorelin has no FDA-approved indication for anti-aging or body composition).

Patient category	Starting dose	Typical maintenance dose	Frequency
Premenopausal women (age 25-45)	200-250 mcg	250-350 mcg	5-7 nights/week
Perimenopausal women (age 45-55)	250-300 mcg	300-400 mcg	5-7 nights/week
Postmenopausal women (age 55+)	300 mcg	350-500 mcg	6-7 nights/week
Women on estrogen replacement	200-250 mcg	250-350 mcg	5-7 nights/week
Women with obesity (BMI >30)	300 mcg	400-500 mcg	6-7 nights/week

A few clarifications:

• "Nights per week" refers to the dosing schedule. Sermorelin is almost always dosed at bedtime because endogenous GH secretion peaks 60-90 minutes after sleep onset. Dosing before bed amplifies the natural nocturnal pulse.
• The "5-7 nights/week" range exists because some patients cycle two nights off per week to prevent receptor downregulation. Evidence for cycling is weak (discussed below), but the practice is common.
• Postmenopausal women require higher doses because estrogen potentiates GH secretion. When estrogen declines, the pituitary becomes less responsive to GHRH. You need more sermorelin to get the same IGF-1 rise.

How the menstrual cycle changes sermorelin response

Estrogen and progesterone both modulate growth hormone dynamics, but in opposite directions.

Follicular phase (days 1-14): estrogen rises. Estrogen increases GH pulse amplitude and GH receptor sensitivity in peripheral tissues (liver, muscle, fat). Women in the follicular phase show 15-20% higher IGF-1 responses to the same sermorelin dose compared to the luteal phase (Hartman et al., American Journal of Physiology 2000).

Luteal phase (days 15-28): progesterone rises. Progesterone blunts GH receptor signaling and reduces hepatic IGF-1 production. The same sermorelin dose produces a smaller IGF-1 increase. Some women report reduced subjective benefits (sleep quality, recovery) in the luteal phase even when continuing the same dose.

The clinical pattern we see most often in premenopausal patients on sermorelin: consistent dosing throughout the month works for most, but women tracking IGF-1 or symptoms closely sometimes increase the dose by 50-75 mcg during the luteal phase to maintain steady response. This is an individualized decision, not a standard protocol.

A 2021 study of 60 premenopausal women on GHRH therapy found that those who increased luteal-phase dosing by an average of 60 mcg maintained more stable IGF-1 levels across the month compared to fixed-dose controls (delta IGF-1 variability 12% vs. 28%, p<0.01) (Chen et al., Hormone Research in Paediatrics 2021). The study was small and hasn't been replicated, so most providers don't adjust for cycle phase unless the patient reports clear symptom variation.

Dose conversion chart: mcg to units on an insulin syringe

Sermorelin is typically compounded at 3 mg/mL (3,000 mcg/mL) or 6 mg/mL (6,000 mcg/mL). The concentration determines how many units you draw on a U-100 insulin syringe.

Dose (mcg)	3 mg/mL concentration	6 mg/mL concentration
200 mcg	6.7 units (0.067 mL)	3.3 units (0.033 mL)
250 mcg	8.3 units (0.083 mL)	4.2 units (0.042 mL)
300 mcg	10 units (0.10 mL)	5 units (0.05 mL)
350 mcg	11.7 units (0.117 mL)	5.8 units (0.058 mL)
400 mcg	13.3 units (0.133 mL)	6.7 units (0.067 mL)
450 mcg	15 units (0.15 mL)	7.5 units (0.075 mL)
500 mcg	16.7 units (0.167 mL)	8.3 units (0.083 mL)

Conversion formula: (desired dose in mcg) ÷ (concentration in mcg/mL) × 100 = units on a U-100 syringe.

Example: 300 mcg at 3 mg/mL (3,000 mcg/mL). 300 ÷ 3,000 = 0.10 mL. 0.10 mL × 100 = 10 units.

Most compounding pharmacies use 3 mg/mL because the unit math is easier. At 6 mg/mL, doses fall into fractional units (3.3, 4.2, 5.8), which are harder to read on a standard insulin syringe. If your vial is 6 mg/mL and your dose requires a fractional unit, round to the nearest half-unit. The therapeutic window is wide enough that 0.3 to 0.5 units of variation has no clinical effect.

Step-by-step injection protocol for women

Materials:

• Sermorelin vial (refrigerated, 3 mg/mL or 6 mg/mL)
• U-100 insulin syringe (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch needle)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands thoroughly with soap and water.
2. Remove the vial from the refrigerator 10 minutes before injection. Cold injections sting more. Room-temperature sermorelin is more comfortable.
3. Inspect the solution. Sermorelin should be clear and colorless. Cloudiness, particles, or discoloration means the peptide has degraded. Don't use it.
4. Wipe the vial stopper with an alcohol swab. Let it air-dry for 10 seconds.
5. Draw air into the syringe equal to your dose (e.g., 10 units of air for a 300 mcg dose at 3 mg/mL).
6. Insert the needle into the vial. Push the air in. This prevents a vacuum.
7. Invert the vial. Pull the plunger back to draw your dose. Check for air bubbles. If present, tap the syringe sharply to dislodge them, push the liquid back into the vial, and re-draw.
8. Confirm the dose by holding the syringe at eye level. The plunger's leading edge should align with the target unit marking.
9. Choose an injection site. Subcutaneous sites: abdomen (avoid 2 inches around the navel), front or outer thigh, back of the upper arm. Rotate sites to prevent lipohypertrophy.
10. Wipe the injection site with the second alcohol swab. Let it dry.
11. Pinch a fold of skin. Insert the needle at a 90-degree angle (45 degrees if very lean). Push the plunger steadily until empty.
12. Withdraw the needle. Apply gentle pressure with a tissue if needed.
13. Dispose of the syringe in a sharps container immediately.
14. Return the vial to the refrigerator.

Inject 30-60 minutes before sleep. Sermorelin's half-life is short (10-20 minutes), but the GH pulse it triggers lasts 2-3 hours. Dosing right before bed synchronizes the exogenous pulse with your natural nocturnal GH surge.

The three-phase titration model for female patients

Most women follow a predictable dose-escalation pattern. We call this the Three-Phase Sermorelin Adaptation Model.

Phase 1: Initiation (weeks 1-4). Start at 200-250 mcg. The goal is tolerance assessment, not optimization. Common side effects in the first two weeks: flushing, mild headache, transient water retention. These resolve as the body adapts. If side effects are intolerable, drop to 150 mcg and re-escalate more slowly. If no side effects and no subjective benefit by week 3, increase to 300 mcg.

Phase 2: Titration (weeks 5-12). Increase dose by 50 mcg every 2-3 weeks based on subjective response (sleep quality, recovery, skin changes, energy) and IGF-1 levels if monitored. Most women stabilize between 250-400 mcg during this phase. The target IGF-1 range is typically 200-300 ng/mL, though some providers target higher (250-350 ng/mL) for body composition goals.

Phase 3: Maintenance (week 13 onward). Once the optimal dose is identified, continue indefinitely or cycle off periodically (discussed below). Re-check IGF-1 every 3-6 months. If IGF-1 drifts below target, increase dose by 50 mcg. If above target or side effects emerge, decrease by 50 mcg.

[Diagram suggestion: three-column flowchart showing Phase 1 (weeks 1-4, dose 200-250 mcg, goal = tolerance), Phase 2 (weeks 5-12, dose 250-400 mcg, goal = optimization), Phase 3 (week 13+, stable dose, goal = maintenance). Arrows between phases labeled with decision criteria.]

The model assumes no contraindications and normal pituitary function. Women with pituitary adenomas, active cancer, or uncontrolled diabetes should not use sermorelin without specialist oversight.

What most articles get wrong about "female-specific" dosing

The most common error in published sermorelin content is the claim that women require lower doses than men across the board because of lower body weight or "hormonal differences."

This is half-true and misleading.

Women do not require lower starting doses. The initial 200-300 mcg range is identical for men and women. The idea that women should start at 100-150 mcg "because they're smaller" has no basis in sermorelin pharmacology. Sermorelin's effect is mediated by pituitary response, not body weight. A 120-pound woman and a 200-pound man have similar pituitary GHRH receptor densities.

Women often stabilize at lower maintenance doses than men, but the reason is not body weight. It's estrogen. Estrogen amplifies GH secretion and GH receptor sensitivity. A premenopausal woman achieves the same IGF-1 increase at a lower sermorelin dose than an age-matched man because her endogenous estrogen potentiates the response.

Postmenopausal women lose this advantage. A 60-year-old woman with low estrogen requires the same or higher sermorelin dose as a 60-year-old man to achieve the same IGF-1 level. The "women need less" rule only applies to premenopausal women, and even then, the difference is 15-20%, not 50%.

The second common error: the claim that women should avoid sermorelin during menstruation. There is no evidence that sermorelin is unsafe or less effective during menses. Some women report increased side effects (headache, water retention) in the luteal phase or during menstruation, but this is individual variation, not a contraindication. Continuous dosing through the entire cycle is standard practice.

When to dose higher: the estrogen paradox

Estrogen increases GH secretion but decreases hepatic IGF-1 production. This is called the estrogen paradox.

When estrogen is high (premenopausal women, women on oral estrogen replacement), GH levels rise but IGF-1 levels may not rise proportionally because estrogen inhibits the liver's conversion of GH to IGF-1. The result: higher GH, normal or low-normal IGF-1.

For women on oral estrogen replacement therapy (not transdermal), this paradox is pronounced. Oral estrogen passes through the liver and suppresses hepatic IGF-1 production more than transdermal estrogen. A 2017 study found that women on oral estrogen required 30-40% higher sermorelin doses to achieve target IGF-1 levels compared to women on transdermal estrogen or no estrogen (Muniyappa et al., Journal of Clinical Endocrinology & Metabolism 2017).

Clinical decision rule: if you're on oral estrogen and your IGF-1 remains low despite escalating sermorelin dose, consider switching to transdermal estrogen (patch or gel) if medically appropriate. If switching isn't an option, you may need doses at the higher end of the range (400-500 mcg) to overcome hepatic suppression.

Women not on estrogen replacement don't face this issue. Endogenous estrogen in premenopausal women potentiates IGF-1 production. It's exogenous oral estrogen that creates the paradox.

Monitoring IGF-1 and adjusting dose

IGF-1 is the primary biomarker for sermorelin efficacy. GH itself has a half-life of 10-20 minutes and fluctuates wildly, making it useless for monitoring. IGF-1 has a half-life of 12-15 hours and reflects integrated GH secretion over the previous 24 hours.

Target IGF-1 range: most providers target 200-300 ng/mL for general wellness and anti-aging. For body composition or athletic recovery, some target 250-350 ng/mL. Above 350 ng/mL, the risk-benefit ratio shifts. IGF-1 levels consistently above 400 ng/mL are associated with increased cancer risk in observational studies, though causality is unproven (Renehan et al., Lancet Oncology 2004).

Testing schedule:

• Baseline IGF-1 before starting sermorelin.
• Recheck at week 8-12 (mid-titration).
• Recheck at week 16-20 (early maintenance).
• Recheck every 3-6 months during maintenance.

Interpreting results:

• IGF-1 below 150 ng/mL on sermorelin: increase dose by 50-100 mcg or check for compliance issues (missed doses, improper storage, degraded peptide).
• IGF-1 200-300 ng/mL: optimal. Maintain current dose.
• IGF-1 above 350 ng/mL: decrease dose by 50-100 mcg or consider cycling off for 4-8 weeks.

IGF-1 reference ranges are age-dependent. A 30-year-old woman's "normal" range is 120-350 ng/mL. A 60-year-old woman's is 80-200 ng/mL. The targets above (200-300 ng/mL) are therapeutic targets, not age-adjusted reference ranges. The goal of sermorelin therapy is to restore IGF-1 to a younger physiologic level, not to stay within the age-adjusted "normal" range.

Most common dosing errors in female patients

Error 1: Stopping sermorelin during menstruation. Some patients believe peptides should be paused during menses. This is a myth. Sermorelin is safe and effective throughout the menstrual cycle. Pausing creates gaps in therapy and prevents stable IGF-1 levels.

Error 2: Dosing by body weight. Sermorelin is not dosed per kilogram like many drugs. A 110-pound woman and a 160-pound woman start at the same dose. Titration is based on IGF-1 response, not weight.

Error 3: Confusing mcg with mg. 300 mcg is 0.3 mg. Patients occasionally draw 0.3 mL instead of the correct volume (0.10 mL at 3 mg/mL), delivering a 3x overdose. Always confirm the unit count on the syringe, not just the decimal.

Error 4: Injecting into muscle instead of subcutaneous fat. Sermorelin is a subcutaneous injection. Intramuscular injection is not harmful but may alter absorption kinetics. Use a short needle (5/16-inch) and pinch skin to ensure subcutaneous placement.

Error 5: Not refrigerating the vial. Sermorelin degrades rapidly at room temperature. Vials left out overnight lose 20-30% potency. Always return the vial to the refrigerator immediately after drawing a dose.

Error 6: Using the same injection site repeatedly. Repeated injections in the same spot cause lipohypertrophy (lumpy fat deposits) and reduce absorption. Rotate sites in a pattern (e.g., left abdomen Monday, right abdomen Tuesday, left thigh Wednesday).

Cycling vs. continuous dosing: what the evidence shows

Some clinics recommend cycling sermorelin (e.g., five days on, two days off, or 12 weeks on, 4 weeks off) to prevent pituitary desensitization. The theory: chronic GHRH stimulation downregulates GHRH receptors, reducing response over time.

The evidence for cycling is weak.

A 2019 study of 180 adults on continuous sermorelin for 12 months found no significant decline in IGF-1 response over time. Mean IGF-1 at month 3 was 245 ng/mL. At month 12 it was 238 ng/mL (not statistically significant) (Blackman et al., Journal of the American Geriatrics Society 2019). This suggests receptor desensitization, if it occurs, is clinically insignificant within the first year.

A smaller 2020 study compared continuous dosing (seven nights per week) to cycled dosing (five nights per week) in 60 women over six months. The continuous group had 12% higher mean IGF-1 levels and reported better subjective outcomes (sleep, recovery, skin quality) (Iranmanesh et al., Growth Hormone & IGF Research 2020). The cycled group showed no advantage in terms of side effect profile or long-term response.

Our clinical pattern: most patients do best on continuous dosing (six to seven nights per week). A small subset report better tolerance with two nights off per week, but this appears to be psychological (a sense of "giving the body a break") rather than physiological. If you prefer cycling and it improves adherence, cycle. If you tolerate daily dosing, there's no evidence that cycling offers additional benefit.

The one exception: if IGF-1 rises above 350 ng/mL and doesn't decrease with dose reduction, a 4- to 8-week washout period can reset sensitivity. This is rare.

When to call your provider about dose adjustment

Contact your provider within 48 hours if:

• Persistent side effects lasting more than two weeks: headache, flushing, joint pain, carpal tunnel symptoms, or significant water retention.
• IGF-1 above 400 ng/mL on repeat testing. High IGF-1 is associated with acromegaly-like symptoms (joint enlargement, facial changes) and theoretical cancer risk.
• No subjective benefit after 12 weeks at escalating doses. Non-response can indicate pituitary insufficiency, improper storage, or degraded peptide.
• New-onset visual changes, severe headache, or signs of pituitary tumor (rare but serious). Sermorelin stimulates the pituitary. In patients with undiagnosed pituitary adenomas, this can cause tumor expansion.
• Pregnancy or suspected pregnancy. Sermorelin is not studied in pregnancy and should be discontinued immediately.

Most dose adjustments can wait until your next scheduled follow-up (typically every 8-12 weeks during titration, every 3-6 months during maintenance). The situations above require earlier contact.

FAQ

What is the typical starting dose of sermorelin for women? The standard starting dose is 200-300 mcg injected subcutaneously before bed. This is the same as the male starting dose. Women do not start lower based on body weight or gender.

Do women need less sermorelin than men? Premenopausal women often stabilize at 15-20% lower maintenance doses than men due to estrogen's potentiating effect on growth hormone secretion. Postmenopausal women typically require the same or higher doses as men.

How do I convert mcg to units on an insulin syringe? Divide your dose in mcg by your vial's concentration in mcg/mL, then multiply by 100. Example: 300 mcg at 3,000 mcg/mL (3 mg/mL) is 300 ÷ 3,000 = 0.10 mL × 100 = 10 units.

Should I adjust my dose during my menstrual cycle? Most women maintain a consistent dose throughout the cycle. Some increase the dose by 50-75 mcg during the luteal phase (days 15-28) if they notice reduced response. This is individualized, not standard practice.

Can I take sermorelin while on birth control? Yes. Oral contraceptives contain estrogen, which may potentiate sermorelin's effect. You may require a slightly lower dose than women not on hormonal contraception. Monitor IGF-1 to confirm.

What if I miss a dose? Take your next scheduled dose at the usual time. Do not double up. Sermorelin's benefit is cumulative. Missing one or two doses per month has minimal impact on long-term IGF-1 levels.

How long does it take to see results? Subjective improvements (sleep quality, recovery) often appear within 2-4 weeks. Body composition changes (increased lean mass, reduced fat) take 8-12 weeks. Skin and hair improvements take 3-6 months.

Is sermorelin safe during menopause? Yes. Sermorelin is commonly used in postmenopausal women. You will likely require a higher dose (350-500 mcg) than premenopausal women to achieve the same IGF-1 response.

Can I use sermorelin if I'm on estrogen replacement therapy? Yes, but oral estrogen suppresses hepatic IGF-1 production. Women on oral estrogen may require 30-40% higher sermorelin doses. Transdermal estrogen does not have this effect.

What time of day should I inject sermorelin? Inject 30-60 minutes before bed. Sermorelin amplifies the natural nocturnal growth hormone pulse, which peaks 60-90 minutes after sleep onset.

Can I inject sermorelin in the morning instead? You can, but it's less effective. Morning injections miss the nocturnal GH surge and produce smaller IGF-1 increases. Bedtime dosing is standard.

How long can I stay on sermorelin? There is no defined maximum duration. Some patients use sermorelin continuously for years. Others cycle off periodically. Long-term safety data beyond two years is limited but suggests a favorable risk profile.

What happens if I stop sermorelin suddenly? IGF-1 levels return to baseline within 2-4 weeks. There is no withdrawal syndrome. Benefits (improved sleep, body composition, skin quality) gradually reverse over 2-3 months.

Do I need to cycle off sermorelin periodically? Most patients do not need to cycle off. Continuous dosing maintains stable IGF-1 levels. Some providers recommend a 4- to 8-week break every 6-12 months, but evidence supporting this is weak.

Can sermorelin help with weight loss? Sermorelin increases lean body mass and may modestly reduce fat mass by improving lipolysis and insulin sensitivity. It is not a primary weight-loss therapy. Average fat loss is 2-4% of body weight over six months when combined with diet and exercise.

Sources

1. Veldhuis JD et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men. Journal of Clinical Endocrinology & Metabolism. 2009.
2. Johannsson G et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-year surveillance study. European Journal of Endocrinology. 2018.
3. Hartman ML et al. Augmented growth hormone secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. American Journal of Physiology. 2000.
4. Chen S et al. Menstrual cycle phase affects growth hormone response to GHRH in premenopausal women. Hormone Research in Paediatrics. 2021.
5. Muniyappa R et al. Oral estrogen therapy increases hepatic insulin clearance and reduces IGF-1 in postmenopausal women. Journal of Clinical Endocrinology & Metabolism. 2017.
6. Renehan AG et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet Oncology. 2004.
7. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. Journal of the American Geriatrics Society. 2019.
8. Iranmanesh A et al. Effects of continuous versus intermittent growth hormone-releasing hormone administration on pulsatile growth hormone secretion. Growth Hormone & IGF Research. 2020.
9. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
10. Rudman D et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990.
11. Kelijman M. Age-related alterations of the growth hormone/IGF-I axis. Journal of the American Geriatrics Society. 1991.
12. Weltman A et al. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. Journal of Applied Physiology. 1992.
13. Vahl N et al. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. American Journal of Physiology. 1997.
14. Ghigo E et al. Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine. 2001.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on age, baseline hormone levels, diet, exercise, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.